Back home
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Contact
Our projects

CRISPNA Bio

Desarrollo de tratamientos terapéuticos eficaces y seguros para el Cáncer con el propósito de devolver la esperanza a pacientes que no tienen otra opción

Visit Website

Description

CRISPNA Bio is a biotechnology company in an early stage with a novel CRISPNA technology, developed by two research groups from the University of Granada.CRISPNA technology combines the versatility of CRISPR/Cas systems with the specificity, stability, and sensitivity of peptide nucleic acids (PNAs). The idea is to use PNAs (rather than RNA) to direct Cas proteins to their DNA or RNA targets. We drive healthcare innovation through strategic licensing and collaborative research, while developing diagnostic and therapeutic solutions for various diseases using our CRISPNA technology.

Current needs

En la actualidad, se encuentran en una fase incipiente de desarrollo, tras haber establecido con éxito la prueba de concepto de su tecnología. Sin embargo, para consolidar aún más sus datos con fines de diagnóstico y, lo que es más importante, para aplicaciones terapéuticas, es esencial seguir trabajando. Es imprescindible conseguir una inversión de 500.000 euros para avanzar en el desarrollo preclínico de la tecnología CRISPNA. Aunque tenemos previsto solicitar proyectos, también es necesaria una inversión privada adicional para impulsar nuestros esfuerzos.

Meet the team

Araceli Aguilar González

Graduated in Biochemistry from the University of Córdoba (2016) and holds a Master's in Regenerative Biomedicine from the University of Granada (2017). Completed a Ph.D. in Biomedicine at GENYO (Granada) under the supervision of Dr. Francisco Martín and Dr. Rosario Mª Sánchez Martín, funded by the Ministry of Education FPU grant, with expertise in CRISPR/Cas9 gene editing, resulting in 6 publications, 1 patent, and the establishment of CRISPNA Bio S.L.; offering over 6 years of experience in genomic editing and teaching experience at the University of Granada's Faculty of Pharmacy.

Carlos Martin-Molina

An experienced Civil Engineer with an Executive MBA, adept at managing large-scale projects and excelling in strategic planning, human resources, and client relations. Co-founder of Bioceramic 2012 and Debla Desarrollo e Infraestructuras, S.L., he currently serves as Manager at Facialteam while contributing to CRISPNA Bio, demonstrating versatility across engineering and healthcare sectors.

Maria Julia Martinez Martinez

CAO and Cofounder. She has over 20 years of experience as a tax and accounting advisor. She has extensive experience in filing declarations with the AEAT, as well as appeals against notifications and claims from both the AEAT and the Junta de Andalucía, with a success rate of over 90%. She also has extensive experience in accounting for SMEs and large companies, presenting all the annual or quarterly tax models for the different administrations.

Francisco Martín Molina

Co-founder. is a Professor at the University of Granada and the Principal Investigator of the Gene and Cellular Therapy group of GENYO. He has over 30 years of experience in the development of new, more efficient, and safer gene transfer systems for the treatment of cancer and rare diseases. He has 13 international patents and more than 80 publications in first-level journals with over 2100 citations. He is also the founder of LentiStem Biotech and Chairman of its Advisory Board.

Juan José Díaz Mochón

Co-founder. Ph.D. Ph.D. in Pharmacy from the University of Granada, serves as a Full Professor at the same university, leading numerous interdisciplinary projects focusing on the development of chemical and biotechnological platforms. With 25 projects undertaken, 10 as principal investigator, he is the founder of 4 spin-offs, co-inventor of 7 patents (4 licensed), and actively involved in entrepreneurship programs at UGR and postgraduate teaching in health entrepreneurship.

Rosario María Sánchez Martín

Cofounder. is a Full Professor at the University of Granada and the Principal Investigator of the Nanochembio group of GENYO. She has carried out 27 regional, national, and international projects, in which she appears as the principal investigator in 12 of them. She is the co-inventor of four patents and a member of the Scientific Advisory Board of Nanogetic S.L., which she founded in 2013.

María Tristán Manzano

Cofounder. Graduated with Honors in Biotechnology from the University of Murcia and holding a Master's in Advanced Immunology from the University of Granada (2016), she pursued her Ph.D. in Biomedicine under the guidance of Prof. Francisco Martín at GENYO (Granada). During her doctoral studies, she co-developed cutting-edge LentiStem technologies for optimizing gene expression control in cells designed for immunotherapy and CAR-T cells.

Noelia Maldonado Pérez

Cofounder. is graduated in Biochemistry in 2017 and obtained a Master's degree in Research in Molecular and Cellular Immunology in 2018 from the University of Granada. She has her PhD in Biomedicine at Genyo focuses on improving chimeric antigen receptor (CAR)-expressing T-cell-based antitumor immunotherapy.

Araceli Aguilar González

Graduated in Biochemistry from the University of Córdoba (2016) and holds a Master's in Regenerative Biomedicine from the University of Granada (2017). Completed a Ph.D. in Biomedicine at GENYO (Granada) under the supervision of Dr. Francisco Martín and Dr. Rosario Mª Sánchez Martín, funded by the Ministry of Education FPU grant, with expertise in CRISPR/Cas9 gene editing, resulting in 6 publications, 1 patent, and the establishment of CRISPNA Bio S.L.; offering over 6 years of experience in genomic editing and teaching experience at the University of Granada's Faculty of Pharmacy.

Maria Julia Martinez Martinez

CAO and Cofounder. She has over 20 years of experience as a tax and accounting advisor. She has extensive experience in filing declarations with the AEAT, as well as appeals against notifications and claims from both the AEAT and the Junta de Andalucía, with a success rate of over 90%. She also has extensive experience in accounting for SMEs and large companies, presenting all the annual or quarterly tax models for the different administrations.

Francisco Martín Molina

Co-founder. is a Professor at the University of Granada and the Principal Investigator of the Gene and Cellular Therapy group of GENYO. He has over 30 years of experience in the development of new, more efficient, and safer gene transfer systems for the treatment of cancer and rare diseases. He has 13 international patents and more than 80 publications in first-level journals with over 2100 citations. He is also the founder of LentiStem Biotech and Chairman of its Advisory Board.

Juan José Díaz Mochón

Co-founder. Ph.D. Ph.D. in Pharmacy from the University of Granada, serves as a Full Professor at the same university, leading numerous interdisciplinary projects focusing on the development of chemical and biotechnological platforms. With 25 projects undertaken, 10 as principal investigator, he is the founder of 4 spin-offs, co-inventor of 7 patents (4 licensed), and actively involved in entrepreneurship programs at UGR and postgraduate teaching in health entrepreneurship.

Rosario María Sánchez Martín

Cofounder. is a Full Professor at the University of Granada and the Principal Investigator of the Nanochembio group of GENYO. She has carried out 27 regional, national, and international projects, in which she appears as the principal investigator in 12 of them. She is the co-inventor of four patents and a member of the Scientific Advisory Board of Nanogetic S.L., which she founded in 2013.

María Tristán Manzano

Cofounder. Graduated with Honors in Biotechnology from the University of Murcia and holding a Master's in Advanced Immunology from the University of Granada (2016), she pursued her Ph.D. in Biomedicine under the guidance of Prof. Francisco Martín at GENYO (Granada). During her doctoral studies, she co-developed cutting-edge LentiStem technologies for optimizing gene expression control in cells designed for immunotherapy and CAR-T cells.

Noelia Maldonado Pérez

Cofounder. is graduated in Biochemistry in 2017 and obtained a Master's degree in Research in Molecular and Cellular Immunology in 2018 from the University of Granada. She has her PhD in Biomedicine at Genyo focuses on improving chimeric antigen receptor (CAR)-expressing T-cell-based antitumor immunotherapy.

Actuación del Campus de excelencia cofinanciadas por la Unión Europea a través del Fondo Europeo de Desarrollo Regional (FEDER) y la Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía.

Proyecto Singular ILIBERIS: Actuaciones Singulares de Transferencia de Conocimiento en el CEI BIOTIC.

Marco por el que se impulsa el desarrollo de Proyectos Singulares de actuaciones de transferencia en los Campus de Excelencia Internacional en las áreas de la Estrategia de Investigación e Innovación para la Especialización Inteligente de Andalucía (RIS3) con cargo al Programa Operativo FEDER 2014-2020 de Andalucía.

AcexHealth